We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Cetuximab as primary treatment for cutaneous squamous cell carcinoma to the neck.
- Authors
Sung Kim; Eleff, Michael; Nicolaou, Nicos
- Abstract
Background. Head and neck cutaneous squamous cell carcinoma (SCC) metastatic to lymph nodes is commonly treated with surgery plus radiotherapy. Methods. We present the case of a 92-year-old man with cutaneous SCC metastatic to the neck (7 cm) who was treated with primary cetuximab and has had a durable complete response for 7 months. Because of his age, comorbidities, and unresectable neck lymphadenopathy, he received primary cetuximab. He received a 400 mg/m2 loading dose and a 250 mg/m2 weekly dose for 3 months and then had to discontinue as a result of other unrelated medical issues. Results. The patient had a complete response by 6 weeks. Seven months after discontinuing cetuximab, he continues to have a complete response. Conclusions. Primary cetuximab for cutaneous SCC metastatic to lymph nodes is an area that bears further investigation because of its apparent efficacy and excellent toxicity profile.
- Subjects
CETUXIMAB; SQUAMOUS cell carcinoma; CANCER treatment; LYMPH node diseases; LYMPH node surgery; HEAD &; neck cancer treatment; CANCER radiotherapy; COMORBIDITY
- Publication
Head & Neck, 2011, Vol 33, Issue 2, p286
- ISSN
1043-3074
- Publication type
Article
- DOI
10.1002/hed.21299